press release

InSphero AG
Wagistrasse 27
CH-8952 Schlieren
Tel: +41 44 515049-0
Fax: +41 44 515049-1
Media Release – For Immediate Distribution
InSphero Launches Multi-donor Human Liver Microtissues for
Prediction of Drug-induced Liver Injury
3D human liver microtissues comprised of pooled hepatocytes from multiple donors
offers more genetically diverse model for DILI detection and prediction.
Schlieren, Switzerland – March 15, 2016 InSphero AG, the leading supplier of easy-to-use
solutions for production, culture, and assessment of organotypic 3D cell culture models, today
announced the launch of 3D InSight™ Multi-donor Human Liver Microtissues, further expanding
the company’s catalog of organotypic 3D models produced using their patented hanging-drop
production technology. The newest liver model is being introduced at the Society of
Toxicology’s 55th Annual Meeting and ToxExpo being held this week in New Orleans, Louisiana.
Failure of drugs during late phases of the drug discovery process costs the pharmaceutical
industry billions of dollars each year, and drug-induced liver injury (DILI) is the primary reason for
post-market drug withdrawal. InSphero 3D InSight™ Human Liver Microtissues provide a more
sensitive preclinical in vitro model for DILI detection and prediction, with the specificity to
accurately distinguish between known hepatotoxicants and structurally-related non-toxic
analogs. The new multi-donor microtissues offer the same structural and functional robustness
of single-donor microtissues, but provide a more diverse genetic background to help mitigate
bias in models resulting from naturally occurring variations in drug-metabolizing Cytochrome
P450 enzymes.
Dr. Jens Kelm, InSphero Chief Scientific Officer and co-founder says, “By pooling hepatocytes
from 5 male and 5 female donors, multi-donor microtissues more closely approximate the
average human response, and extend donor lot availability to ensure a long-term supply of cells
for microtissue production. This makes them an ideal tool for in vitro DILI detection and
prediction, compound toxicity screening, mechanistic toxicology, and DMPK studies.”
Multi-donor microtissues are available as hepatocyte-only monocultures, or as co-cultures with
Kupffer cells, enabling detection of immune-mediated toxicity.
To find out more about 3D InSight™ Multi-donor Human Liver Microtissues, or to learn more
about InSphero visit
For more information about InSphero, visit
InSphero contacts
InSphero AG
Wagistrasse 27
CH-8952 Schlieren
Tel: +41 44 515049-0
Fax: +41 44 515049-1
Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
[email protected]
Dr. Jens M. Kelm
Chief Scientific Officer and Co-founder
Phone +41 44 5150490
[email protected]
About InSphero
InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for
production, culture and assessment of more organotypic 3D cell culture models. The company’s
patented 3D cell culture platforms and methods enable large-scale, reproducible production of a
broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart,
brain and skin. These models and contract research services utilizing them help to identify
promising drugs and toxic liabilities with greater predictivity at early development stages, enabling
better pre-clinical decision making, saving development cost, and shortening time to market.
InSphero technologies drive significant findings in peer-reviewed journals, through collaborative
projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest
government institutions and pharmaceutical, chemical and cosmetics companies. This 3D knowhow is also being applied in the diagnostics field to aid development of personalized
chemotherapeutic strategies for the treatment of cancer.
Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with
subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized
for its scientific and commercial achievements with a number of national and international awards.
Follow us on Twitter and